Baidu
map

Br J Cancer:H2拮抗剂雷尼替丁在紫杉醇治疗期间的附加价值

2021-03-25 xiaozeng MedSci原创

紫杉醇作为全球最常用的抗癌药物之一。其可以有效的治疗包括乳腺癌、肺癌、卵巢癌、头颈癌和食道癌在内的多种恶性肿瘤。

紫杉醇作为全球最常用的抗癌药物之一。其可以有效的治疗包括乳腺癌、肺癌、卵巢癌、头颈癌和食道癌在内的多种恶性肿瘤。然而,由于紫杉醇具有疏水性,因此必须在Cremophor- EL(聚氧乙烯蓖麻油衍生物)中进行乳化,这也使得在紫杉醇输注期间经常会出现超敏反应(HSR)。

雷尼替丁(Ranitidine)是一种用于治疗胃十二指肠反流和溃疡病的药物。其作为一种H2阻滞剂,可用于预防因紫杉醇输注引起的HSR。然而,雷尼替丁在这种术前用药方案中的附加价值目前仍存在争议。因此,该研究旨在比较在紫杉醇治疗期间,包括雷尼替丁在内的标准方案与不含雷尼替丁的方案之间的HSR反应发生率。

该项前瞻性、非劣效性研究比较了包括地塞米松(dexamethasone)、克立马丁(clemastine)和雷尼替丁的标准术前用药方案和不含雷尼替丁的术前用药方案。该研究的主要结局为HSR≥3级的发生率。

患者的分布

干预前组(使用雷尼替丁)和干预后组(不使用雷尼替丁)均包括了183例患者。结果显示,干预前组HSR≥3级的发生率为4.4%(N=8),而干预后组为1.6%(N=3),二者相差-2.7%。而90%置信区间(CI)的上限未超过预定义的非劣性余量+6%。

单变量和多变量分析结果

因此,上述的研究结果显示,没有雷尼替丁的治疗方案并不逊于雷尼替丁的预防方案。


原始出处:

Cox, J.M., van Doorn, L., Malmberg, R. et al. The added value of H2 antagonists in premedication regimens during paclitaxel treatment. Br J Cancer (24 March 2021).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=952354, encodeId=87f99523541e, content=涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d09d5473267, createdName=ms6000000442074121, createdTime=Tue Mar 30 12:24:04 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511784, encodeId=92ab1511e8470, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Sat Mar 27 14:43:41 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951420, encodeId=9dd4951420ad, content=用西米替丁什么情况啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/15/376de562705ccd8a43dfc3b347a3b5ff.jpg, createdBy=f58a2381667, createdName=蝴蝶A , createdTime=Fri Mar 26 17:00:38 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951320, encodeId=92f795132004, content=涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210326/d30f63d105ce41d788cd90b7a867eeb9/2e3e7fecd13141a8a4b3d956d350e164.jpg, createdBy=80835473376, createdName=Xena, createdTime=Fri Mar 26 07:56:34 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951312, encodeId=3d95951312e6, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Fri Mar 26 06:24:39 CST 2021, time=2021-03-26, status=1, ipAttribution=)]
    2021-03-30 ms6000000442074121

    涨知识了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=952354, encodeId=87f99523541e, content=涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d09d5473267, createdName=ms6000000442074121, createdTime=Tue Mar 30 12:24:04 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511784, encodeId=92ab1511e8470, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Sat Mar 27 14:43:41 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951420, encodeId=9dd4951420ad, content=用西米替丁什么情况啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/15/376de562705ccd8a43dfc3b347a3b5ff.jpg, createdBy=f58a2381667, createdName=蝴蝶A , createdTime=Fri Mar 26 17:00:38 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951320, encodeId=92f795132004, content=涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210326/d30f63d105ce41d788cd90b7a867eeb9/2e3e7fecd13141a8a4b3d956d350e164.jpg, createdBy=80835473376, createdName=Xena, createdTime=Fri Mar 26 07:56:34 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951312, encodeId=3d95951312e6, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Fri Mar 26 06:24:39 CST 2021, time=2021-03-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=952354, encodeId=87f99523541e, content=涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d09d5473267, createdName=ms6000000442074121, createdTime=Tue Mar 30 12:24:04 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511784, encodeId=92ab1511e8470, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Sat Mar 27 14:43:41 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951420, encodeId=9dd4951420ad, content=用西米替丁什么情况啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/15/376de562705ccd8a43dfc3b347a3b5ff.jpg, createdBy=f58a2381667, createdName=蝴蝶A , createdTime=Fri Mar 26 17:00:38 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951320, encodeId=92f795132004, content=涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210326/d30f63d105ce41d788cd90b7a867eeb9/2e3e7fecd13141a8a4b3d956d350e164.jpg, createdBy=80835473376, createdName=Xena, createdTime=Fri Mar 26 07:56:34 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951312, encodeId=3d95951312e6, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Fri Mar 26 06:24:39 CST 2021, time=2021-03-26, status=1, ipAttribution=)]
    2021-03-26 蝴蝶A

    用西米替丁什么情况啊

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=952354, encodeId=87f99523541e, content=涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d09d5473267, createdName=ms6000000442074121, createdTime=Tue Mar 30 12:24:04 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511784, encodeId=92ab1511e8470, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Sat Mar 27 14:43:41 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951420, encodeId=9dd4951420ad, content=用西米替丁什么情况啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/15/376de562705ccd8a43dfc3b347a3b5ff.jpg, createdBy=f58a2381667, createdName=蝴蝶A , createdTime=Fri Mar 26 17:00:38 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951320, encodeId=92f795132004, content=涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210326/d30f63d105ce41d788cd90b7a867eeb9/2e3e7fecd13141a8a4b3d956d350e164.jpg, createdBy=80835473376, createdName=Xena, createdTime=Fri Mar 26 07:56:34 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951312, encodeId=3d95951312e6, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Fri Mar 26 06:24:39 CST 2021, time=2021-03-26, status=1, ipAttribution=)]
    2021-03-26 Xena

    涨知识了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=952354, encodeId=87f99523541e, content=涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d09d5473267, createdName=ms6000000442074121, createdTime=Tue Mar 30 12:24:04 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511784, encodeId=92ab1511e8470, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Sat Mar 27 14:43:41 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951420, encodeId=9dd4951420ad, content=用西米替丁什么情况啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/15/376de562705ccd8a43dfc3b347a3b5ff.jpg, createdBy=f58a2381667, createdName=蝴蝶A , createdTime=Fri Mar 26 17:00:38 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951320, encodeId=92f795132004, content=涨知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210326/d30f63d105ce41d788cd90b7a867eeb9/2e3e7fecd13141a8a4b3d956d350e164.jpg, createdBy=80835473376, createdName=Xena, createdTime=Fri Mar 26 07:56:34 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951312, encodeId=3d95951312e6, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Fri Mar 26 06:24:39 CST 2021, time=2021-03-26, status=1, ipAttribution=)]
    2021-03-26 易水河

    学习学习

    0

相关资讯

Prostate:去势抵抗性前列腺癌中雄激素受体信号靶向治疗和紫杉醇化疗能够诱导内脏转移

内脏转移(VM)是前列腺癌(PC)的一个重要的不良预后因素,在去势敏感状态下不常见,但在去势抗性产生后经常观察到。然而,VM的部位、出现时间和发生率还未完全阐明。

J Vasc Interv Radiol:两年研究结果表明DCB血管成形术对AVFs长期安全且有效

本项随机试验对比了紫杉醇涂层与非涂层球囊血管成形术后血管准备与超高压经皮穿刺血管成形术(PTA)在血液透析动静脉瘘(AVFs)中的2年结果,该研究结果已在线发表于J Vasc Interv Radio

Clin Cancer Res:纳武单抗+紫杉醇+雷莫芦单抗治疗晚期胃癌的疗效未来可期!

胃癌是体细胞突变率第五高的癌症。在胃癌细胞和癌组织浸润T细胞中常见PD-1、PD-L1及其配体过表达。但抗PD-1/PD-L1抗体用于晚期胃癌(AGC)中的疗效尚无明确结论。

Lancet oncol:ICON8试验| 卵巢、输卵管、腹膜癌经卡铂-紫杉醇一线新辅助化疗后的客观缓解率

本文报道了ICON8试验中采用以铂类为基础的新辅助化疗继以DPS治疗的患者的RECIST和妇科恶性肿瘤协会(GCIG)CA125反应。

NEJM:药物涂层球囊用于预防功能失调性动静脉瘘术后再狭窄

在功能失调性动静脉瘘狭窄性病变术后接受紫杉醇药物涂层球囊抗逆转录治疗可改善患者预后,提高血管通畅率

J Clin Oncol:贝伐单抗+卡铂+紫杉醇可明显改善转移性粘膜黑色素瘤的预后

粘膜黑色素瘤(MM)是一种高度血管化的肿瘤,预后极差。贝伐单抗+卡铂+紫杉醇可明显改善转移性粘膜黑色素瘤的预后,一起来看看吧~

Baidu
map
Baidu
map
Baidu
map